CA
NZ
UK
AU
IND
US
…
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Allogene Therapeutics is a clinical-stage biotechnology company developing off-the-shelf allogeneic CAR T-cell therapies for hematologic malignancies and solid tumors. Its long-term growth may be driven by successful clinical data and regulatory approvals for allogeneic CAR-T candidates, scalable manufacturing that lowers time-to-treatment versus autologous CAR-T, and expansion into multiple oncology indications, which could address large unmet needs and support commercialization.
Key investment risks include significant clinical and regulatory uncertainty, manufacturing and supply-chain scalability challenges, intense competition from autologous and alternative cell therapies, and ongoing capital requirements to fund development and commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -190.89M | -257.15M | -327.26M | -332.63M | -257.00M |
| Net income | -190.89M | -257.59M | -327.26M | -329.81M | -244.84M |
| Selling general administrative | 56.78M | 65.20M | 71.67M | 79.31M | 74.11M |
| Gross profit | -12.36M | 0.02M | 0.10M | 0.24M | 38.49M |
| Reconciled depreciation | 12.36M | 13.64M | 13.79M | 14.29M | 10.45M |
| Ebit | -206.93M | -256.97M | -327.26M | -349.74M | -266.25M |
| Ebitda | -194.57M | -243.33M | -313.07M | -335.45M | -255.79M |
| Depreciation and amortization | 12.36M | 13.64M | 14.20M | 14.29M | 10.45M |
| Non operating income net other | - | - | - | - | -1.21M |
| Operating income | -206.93M | -273.20M | -327.74M | -335.45M | -255.79M |
| Other operating expenses | 206.93M | 273.22M | 327.83M | 335.69M | 294.28M |
| Interest expense | 1.07M | 0.18M | 17.11M | -17.11M | 10.45M |
| Tax provision | 0.00M | 0.44M | 0.00M | - | 0.00M |
| Interest income | 19.29M | 20.15M | 14.80M | 4.57M | 1.71M |
| Net interest income | 18.21M | 19.97M | 14.80M | 4.57M | 1.71M |
| Income tax expense | - | 0.44M | -2.82M | -2.82M | -12.17M |
| Total revenue | 0.00M | 0.02M | 0.10M | 0.24M | 38.49M |
| Total operating expenses | 194.57M | 273.22M | 327.83M | 335.69M | 294.28M |
| Cost of revenue | 12.36M | 13.64M | 14.20M | - | - |
| Total other income expense net | 16.05M | 16.05M | 0.47M | 2.82M | -1.21M |
| Net income from continuing ops | -190.89M | -257.59M | -332.86M | -332.63M | -257.00M |
| Net income applicable to common shares | - | - | - | -332.63M | -257.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 415.90M | 548.71M | 642.84M | 817.08M | 1038.63M |
| Other current assets | 6.04M | 9.01M | 10.42M | 11.50M | 14.02M |
| Total liab | 123.36M | 126.53M | 130.60M | 151.21M | 122.23M |
| Total stockholder equity | 292.54M | 422.18M | 512.23M | 665.87M | 916.41M |
| Other current liab | 28.24M | 22.62M | 24.32M | 33.74M | 37.50M |
| Common stock | 0.23M | 0.21M | 0.17M | 0.14M | 0.14M |
| Capital stock | 0.23M | 0.21M | 0.17M | 0.14M | 0.14M |
| Retained earnings | -2010.71M | -1819.82M | -1562.23M | -1235.98M | -903.35M |
| Other liab | - | - | - | 1.57M | 4.12M |
| Other assets | - | - | - | 16.86M | 16.11M |
| Cash | 51.69M | 75.22M | 83.16M | 576.47M | 809.48M |
| Total current liabilities | 32.51M | 35.52M | 37.08M | 54.52M | 48.17M |
| Current deferred revenue | - | - | 0.09M | 0.89M | 0.42M |
| Net debt | 23.36M | 15.54M | 11.97M | -481.35M | -739.55M |
| Short term debt | - | 7.51M | 6.78M | 6.00M | - |
| Short long term debt total | 75.05M | 90.76M | 95.12M | 95.12M | 69.93M |
| Other stockholder equity | 2302.75M | 2241.88M | 2075.25M | 1911.63M | 1822.18M |
| Property plant equipment | - | - | - | 196.43M | 122.99M |
| Total current assets | 257.75M | 303.39M | 459.12M | 528.82M | 809.48M |
| Long term investments | 8.04M | 80.67M | 3.65M | 71.97M | 352.18M |
| Net tangible assets | - | - | - | 665.87M | 916.41M |
| Short term investments | 198.52M | 217.26M | 365.54M | 455.42M | 283.99M |
| Net receivables | 1.50M | 1.90M | - | 3.30M | 5.82M |
| Accounts payable | 4.27M | 5.39M | 5.90M | 13.89M | 10.26M |
| Accumulated other comprehensive income | 0.27M | -0.09M | -0.95M | -9.93M | -2.57M |
| Common stock total equity | - | - | - | - | 0.14M |
| Retained earnings total equity | - | - | - | - | -903.35M |
| Non currrent assets other | 37.39M | 33.39M | 16.90M | 32.67M | -322.05M |
| Non current assets total | 158.16M | 245.32M | 183.72M | 288.25M | 229.15M |
| Capital lease obligations | 83.25M | 90.76M | 95.12M | 101.12M | 69.93M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 95.94M | 75.69M | 145.43M | 106.16M | 185.10M |
| Change to liabilities | - | - | - | 5.33M | 3.93M |
| Total cashflows from investing activities | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Total cash from financing activities | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
| Change to operating activities | - | - | - | -1.62M | 7.25M |
| Net income | -190.89M | -257.59M | -327.26M | -332.63M | -257.00M |
| Change in cash | -23.53M | -7.94M | 21.25M | -111.41M | -9.19M |
| Begin period cash flow | 85.51M | 93.45M | 72.20M | 183.61M | 192.80M |
| End period cash flow | 61.98M | 85.51M | 93.45M | 72.20M | 183.61M |
| Total cash from operating activities | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Issuance of capital stock | 22.35M | 112.05M | 91.11M | 0.00M | 0.00M |
| Depreciation | 12.36M | 13.64M | 14.20M | 14.29M | 10.45M |
| Other cashflows from investing activities | - | - | 111.35M | - | - |
| Sale purchase of stock | 0.90M | 1.53M | 2.46M | 2.46M | 3.62M |
| Other cashflows from financing activities | 6.91M | 2.28M | 4.58M | 106.16M | 8.35M |
| Change to netincome | - | - | - | 94.11M | 80.82M |
| Capital expenditures | 0.39M | 0.69M | 1.52M | 5.19M | 21.45M |
| Cash flows other operating | - | - | - | - | -29.96M |
| Cash and cash equivalents changes | - | - | - | - | -9.19M |
| Change in working capital | -10.88M | -24.80M | -15.30M | 3.71M | -32.09M |
| Stock based compensation | 37.64M | 51.74M | 65.95M | 83.60M | 80.82M |
| Other non cash items | 2.52M | 16.26M | 24.69M | 2.43M | 2.61M |
| Free cash flow | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics Inc |
-0.04 3.20% |
1.21 | - | - | 7784.36 | 2.85 | 3859.62 | -1.04 |
| NVO Novo Nordisk A/S |
0.08 0.20% |
39.13 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.65 0.33% |
807.67 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
210 East Grand Avenue, South San Francisco, CA, United States, 94080
650 457 2700
150
| Name | Title | Year Born |
|---|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. | Co-Founder & Exec. Chairman | 1949 |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, Pres, CEO & Director | 1960 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 1977 |
| Dr. Eric Thomas Schmidt Ph.D. | Chief Financial Officer | 1970 |
| Dr. Alison Moore Ph.D. | Chief Technical Officer | 1967 |
| Mr. Veer Bhavnagri | Gen. Counsel & Compliance Officer | 1983 |
| Dr. Rafael G. Amado M.D. | Exec. VP of R&D | 1964 |
| Ms. Barbra Sasu | Chief Scientific Officer | NA |
| Mr. Stephen Cheng | Chief Information Officer | NA |
| Ms. Christine Cassiano | Chief Communications Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...